CARLOS
SOLANO VERCET

2024

1. Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease

   Bone Marrow Transplantation, Vol. 59, Núm. 8, pp. 1118-1126

2. Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis

   Bone Marrow Transplantation

3. Comparative performance of the Platelia Aspergillus Antigen and Aspergillus Galactomannan antigen Virclia Monotest immunoassays in serum and lower respiratory tract specimens: a "real-life" experience

   Microbiology Spectrum, Vol. 12, Núm. 8

4. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil

   Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1025.e1-1025.e14

5. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome

   Clinical Neurophysiology, Vol. 163, pp. 132-142

6. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor

   Bone Marrow Transplantation, Vol. 59, Núm. 5, pp. 597-603

7. Incidence and clinical correlates of NFE2 mutations in myeloid neoplasms

   British Journal of Haematology

8. Letermovir use may impact on the Cytomegalovirus DNA fragmentation profile in plasma from allogeneic hematopoietic stem cell transplant recipients

   Journal of Medical Virology, Vol. 96, Núm. 3

9. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

   Frontiers in Oncology, Vol. 14

10. PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

    Blood Advances, Vol. 8, Núm. 15, pp. 3985-3992

11. Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 7, pp. 1427-1436

12. Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    American Journal of Hematology, Vol. 99, Núm. 7, pp. 1250-1256

13. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14

14. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies

    Bone Marrow Transplantation, Vol. 59, Núm. 10, pp. 1369-1375

15. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    The Lancet Haematology, Vol. 11, Núm. 2, pp. e147-e159

16. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

17. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)

    Cytotherapy, Vol. 26, Núm. 1, pp. 25-35

18. Torque Teno Virus DNA Load in Blood as an Immune Status Biomarker in Adult Hematological Patients: The State of the Art and Future Prospects

    Viruses, Vol. 16, Núm. 3

19. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100

20. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 562-572